Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its proprietary nasal delivery system is being utilized in LTR Pharma Limited’s (ASX:LTP) Phase II clinical study of SPONTAN®, an investigational intranasal spray under development for the treatment of erectile dysfunction. This milestone reflects Aptar Pharma’s continued commitment to supporting intranasal drug delivery technologies and supporting the development of innovative, patient-centric therapies.

LTR Pharma recently announced the dosing of the first patients in the Phase II study of SPONTAN®, which is evaluating the safety, tolerability and pharmacokinetic profile of LTR Pharma’s rapid acting intranasal spray, supporting continued clinical development and advancement along the regulatory pathway.

Aptar Pharma’s nasal spray platform is a multidose delivery system designed to deliver accurate and consistent dosing of prescription drug products administered via the nose, supporting reliable intranasal administration throughout clinical development.

This collaboration, supported by Aptar Pharma companies Nanopharm and Noble, helps reinforce Aptar Pharma’s position as a trusted partner in advancing complex intranasal therapies through robust delivery platforms and deep regulatory and technical expertise. Nanopharm developed and optimized the formulation to support the intended product profile, supported by analytical services demonstrating drug product and device performance alongside stability, while Noble is delivering end‑to‑end human factors and risk management support to enhance regulatory readiness and validate usability.

Lee Rodne, Executive Chairman of LTR Pharma, said, “As we progress SPONTAN® through Phase II, robust and reproducible intranasal delivery is central to our development strategy. Partnering with Aptar Pharma provides us with a proven delivery platform supported by deep formulation, analytical and human factors expertise, strengthening the foundation of our clinical and regulatory pathway.”

Alex Theodorakis, President, Aptar Pharma Prescription, added, “Reliable nasal drug delivery is critical as programs move through clinical development, and we are pleased to support LTR Pharma as it advances an innovative intranasal treatment that uses Aptar Pharma’s proprietary delivery technology”.

Read full press release.